First Patient Receives ALETA-001 in Phase 1/2 Trial for Relapsed/Refractory B-Cell Cancer

3 June 2024
A significant advancement in the field of immuno-oncology has been announced by Aleta Biotherapeutics, a clinical-stage company specializing in CAR T-Cell Engager (CTE) platforms. The company has initiated a Phase 1/2 clinical trial for its innovative biologic CAR T-Cell Engager, ALETA-001, which is designed to enhance the efficacy of cancer treatments for patients with B-cell malignancies. The trial marks a crucial step towards offering a novel therapeutic option for individuals whose cancers have become resistant or relapsed following CD19-targeted CAR T-cell therapy.

The trial is being sponsored and conducted by Cancer Research UK’s Centre for Drug Development, a renowned institution with a track record of developing and bringing new cancer treatments to the market. The trial is an open-label, dose-expansion study aimed at assessing the safety, tolerability, and pharmacological effects of ALETA-001, as well as its early clinical efficacy as a standalone treatment.

Dr. Paul Rennert, President and Chief Scientific Officer of Aleta Biotherapeutics, expressed his enthusiasm for the clinical evaluation of ALETA-001, highlighting its potential to restore and amplify the effectiveness of CAR T-cells in eliminating cancer cells. The treatment is expected to provide a much-needed alternative for cancer patients whose existing CAR T-cell therapies have ceased to be effective.

ALETA-001 is a unique molecule with a novel mechanism of action. It coats tumor cells with a high density of target antigens, thereby enhancing the ability of activated CAR T-cells to target and destroy cancer cells. This innovative approach is being explored to improve outcomes for patients with lymphomas who have a poor prognosis after experiencing disease progression post CAR T-cell therapy.

Dr. Lars Erwig, Director of Drug Development at Cancer Research UK, emphasized the importance of ALETA-001 in offering a better chance for a successful treatment outcome for patients with blood cancers who have relapsed following CD19-directed CAR T-cell therapy. The clinical potential of ALETA-001 is seen as transformative for patient treatment journeys, potentially offering life-saving benefits.

Aleta Biotherapeutics is at the forefront of transforming cancer treatment by enhancing the effectiveness of CAR T-cell therapies. The company's multi-antigen CAR T Engagers (CTEs) are potent biologic therapies that aim to produce deeper and more durable responses in patients. ALETA-001, the lead clinical program, is specifically designed for B-cell malignancies in patients at risk of treatment failure following CD19-directed CAR T-cell therapy.

Aleta has received significant clinical support and funding from Cancer Research UK for the ALETA-001 trial and has been granted a UK Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA). This designation is reserved for medicines addressing life-threatening conditions with significant patient or public health needs.

The Cancer Research UK Centre for Drug Development has been instrumental in the development of over 160 potential new anti-cancer agents, with six already on the market and 13 others in active development. The center's expertise and resources are expected to play a pivotal role in the success of the ALETA-001 clinical trial.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!